Vivos Inc financial data

Symbol
RDGL on OTC
Location
719 Jadwin Avenue, Richland, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ADVANCED MEDICAL ISOTOPE Corp (to 12/18/2017)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.07K % -38.8%
Debt-to-equity 10.4 % +69.9%
Return On Equity -196 % -52.2%
Return On Assets -177 % -46.3%
Operating Margin -10.9K % -29.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 418M shares +12.7%
Common Stock, Shares, Outstanding 418M shares +12.7%
Entity Public Float 36.7M USD 0%
Common Stock, Value, Issued 418K USD +12.7%
Weighted Average Number of Shares Outstanding, Basic 403M shares +9.57%
Weighted Average Number of Shares Outstanding, Diluted 403M shares +9.57%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 25K USD -1.96%
Research and Development Expense 670K USD +109%
General and Administrative Expense 143K USD -21%
Operating Income (Loss) -2.73M USD -27.2%
Nonoperating Income (Expense) 18.9K USD +58.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.81M USD -31.5%
Net Income (Loss) Attributable to Parent -2.81M USD -31.5%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.72M USD -1.39%
Accounts Receivable, after Allowance for Credit Loss, Current 13.5K USD +125%
Assets, Current 1.77M USD -1.12%
Assets 1.77M USD -1.12%
Liabilities, Current 167K USD +47.6%
Liabilities 167K USD +47.6%
Common Stocks, Including Additional Paid in Capital 130K USD
Retained Earnings (Accumulated Deficit) -83.5M USD -3.48%
Stockholders' Equity Attributable to Parent 1.6M USD -4.4%
Liabilities and Equity 1.77M USD -1.12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -351K USD -19.7%
Net Cash Provided by (Used in) Financing Activities 130K USD
Common Stock, Shares Authorized 950M shares 0%
Common Stock, Shares, Issued 418M shares +12.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -221K USD +24.6%
Deferred Tax Assets, Valuation Allowance 6.84M USD +5.23%
Deferred Tax Assets, Operating Loss Carryforwards 6.84M USD +5.23%
Preferred Stock, Shares Authorized 20M shares 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%